Secondary Logo

Journal Logo

Lymphoma

  • Creator:   Chinese Medical Journal
  • Updated:   3/24/2021
  • Contains:  6 items
Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the body. When somebody has lymphoma, lymphocytes change and grow out of control. There are two main types of lymphoma:1.Non-Hodgkin: Most people with lymphoma have this type.2.Hodgkin. Non-Hodgkin and Hodgkin lymphoma involve different types of lymphocyte cells. Every type of lymphoma grows at a different rate and responds differently to treatment.

Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis

Zheng, Xiao-Hong; Zhang, Xi-You; Dong, Qian-Qian; More

Chinese Medical Journal. 133(1):74-85, January 5, 2020.

Highlight: CAR-T cell treatment is safe for clinical application; however, toxicity effects should be monitored.

Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysis

Huang, Da-Yong; Hu, Yi-Fei; Wei, Na; More

Chinese Medical Journal. 132(3):294-301, February 5, 2019.

Highlight: The international prognostic index score is a comparatively robust indicator of prognosis at 3 quartiles, and serum erythrocyte sedimentation rate is stable at the middle 2 quartiles section when adjusted for hemophagocytic lymphohistiocytosis. Quantile regression can be used to observe detailed impacts of the predictors on overall survival.

A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma

Liu, Peng; Han, Ying; Jiang, Shi-Yu; More

Chinese Medical Journal. 132(15):1807-1814, August 5, 2019.

Highlight: In comparison to patients aged 61 to 69 years, those aged ≥70 years have poorer survival. Prolonged survival is obtainable with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-like in elderly Chinese patients in all age groups, indicating that the R-CHOP-like regimen should be considered for this population, even for those aged 70 years or older.

R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms

Wang, Liang; Li, Lin-Rong

Chinese Medical Journal. 134(3):253-260, February 5, 2021.

Highlight: This paper discussed the potential R-CHOP resistance mechanisms and proposed valuable biomarkers that can predict R - CHOP treatment resistance in the view of tumor biology (Diffuse large B cell lymphoma [DLBCL] cell origin, clonal evolution, tumor microenvironment and multi-drug resistance), potential molecular targets involving drug resistance, and epigenetic change, and also guide the treatment strategies towards relapsed/refractory DLBCL.

Prognostic significance of locally invaded sites and tissue types in patients with nasal extranodal natural-killer/T-cell lymphoma: a single-center retrospective analysis

Dong, Ge-Hong; Li, Yong; Dong, Ji-Yong; More

Chinese Medical Journal. 132(11):1305-1313, June 5, 2019.

Highlight: Imaging can accurately detect Extranodal natural killer/T-cell lymphoma (ENKTL) invasion of adjacent structures (AS), soft tissue, and bone. Involvement of local soft tissue or bone was significantly associated with lower 2-year overall survival (OS) rates. Involvements of the cheek or facial muscle, as well as maxilla bone, are independent predictors of lower 2-year OS rates in ENKTL patients.

Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment

Zhang, Yan; Zhou, Dao-Bin

Chinese Medical Journal. 133(12):1462-1469, June 20, 2020.

Highlight: Primary central nervous system lymphoma (PCNSL) is a rare group of extra-nodal non-Hodgkin lymphoma which is confined to the central nervous system or eyes.The prognosis of PCNSL has improved mainly due to the introduction and wide-spread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Gene expression profiling and next-generation sequencing analyses have revealed mutations that induce activation of nuclear factor-κB, B cell antigen receptor, and Janus kinases/signal transducer and activator of transcription proteins signal pathways. In particular, lenalidomide and ibrutinib have demonstrated durable efficiency.